Nurix Therapeutics, Inc. NRIX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s deferred revenue?
- Nurix Therapeutics, Inc. (NRIX) reported deferred revenue of $18.75M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Nurix Therapeutics, Inc.'s deferred revenue decreased by 38.7% year-over-year, from $30.59M to $18.75M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s deferred revenue has grown at a -11.7% compound annual growth rate (CAGR), from $32.8M to $17.58M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.